FI952302A - Pyran-2-onit ja 5,6-dihydropyranonit, jotka ovat käyttökelpoisia HIV:n ja muiden retrovirusten hoidossa - Google Patents

Pyran-2-onit ja 5,6-dihydropyranonit, jotka ovat käyttökelpoisia HIV:n ja muiden retrovirusten hoidossa Download PDF

Info

Publication number
FI952302A
FI952302A FI952302A FI952302A FI952302A FI 952302 A FI952302 A FI 952302A FI 952302 A FI952302 A FI 952302A FI 952302 A FI952302 A FI 952302A FI 952302 A FI952302 A FI 952302A
Authority
FI
Finland
Prior art keywords
ones
pyran
dihydropyran
retroviruses
hiv
Prior art date
Application number
FI952302A
Other languages
English (en)
Swedish (sv)
Other versions
FI120399B (fi
FI952302A0 (fi
Inventor
Suvit Thaisrivongs
Chih-Ping Yang
Joseph Walter Strohbach
Steven Ronald Turner
Donna Lee Romero
Louis L Skaletzki
Paul Andrian Aristoff
Ronald B Gammill
Paul D Johnson
Harvey Irving Skulnick
Richard C Piper
Ruben A Tommasi
Qingwei Zhang
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of FI952302A publication Critical patent/FI952302A/fi
Publication of FI952302A0 publication Critical patent/FI952302A0/fi
Application granted granted Critical
Publication of FI120399B publication Critical patent/FI120399B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
FI952302A 1992-11-13 1995-05-11 Menetelmä pyran-2-onien ja 5,6-dihydropyranonien valmistamiseksi, jotka ovat käyttökelpoisia HIV:n ja muiden retrovirusten hoidossa FI120399B (fi)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US97534392A 1992-11-13 1992-11-13
US97534392 1992-11-13
US9087693A 1993-07-13 1993-07-13
US9087693 1993-07-13
US13064193A 1993-10-01 1993-10-01
US13064193 1993-10-01
PCT/US1993/010645 WO1994011361A1 (en) 1992-11-13 1993-11-09 Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hiv and other retroviruses
US9310645 1993-11-09

Publications (3)

Publication Number Publication Date
FI952302A true FI952302A (fi) 1995-05-11
FI952302A0 FI952302A0 (fi) 1995-05-11
FI120399B FI120399B (fi) 2009-10-15

Family

ID=27376682

Family Applications (1)

Application Number Title Priority Date Filing Date
FI952302A FI120399B (fi) 1992-11-13 1995-05-11 Menetelmä pyran-2-onien ja 5,6-dihydropyranonien valmistamiseksi, jotka ovat käyttökelpoisia HIV:n ja muiden retrovirusten hoidossa

Country Status (26)

Country Link
EP (2) EP1203770B1 (fi)
JP (1) JP3583127B2 (fi)
KR (1) KR100314975B1 (fi)
CN (1) CN1040321C (fi)
AT (2) ATE290531T1 (fi)
AU (1) AU687368B2 (fi)
BR (1) BR9307451A (fi)
CA (1) CA2145661C (fi)
CZ (1) CZ291853B6 (fi)
DE (2) DE69333771T2 (fi)
DK (2) DK0668860T3 (fi)
ES (2) ES2182837T3 (fi)
FI (1) FI120399B (fi)
GE (1) GEP20094660B (fi)
HU (1) HU228126B1 (fi)
IL (1) IL107556A (fi)
LV (1) LV13088B (fi)
MY (1) MY119031A (fi)
NO (1) NO319914B1 (fi)
NZ (1) NZ258013A (fi)
PL (1) PL178653B1 (fi)
PT (2) PT668860E (fi)
RU (1) RU2134691C1 (fi)
SK (1) SK285001B6 (fi)
WO (1) WO1994011361A1 (fi)
ZA (1) ZA938019B (fi)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW354294B (en) * 1993-09-17 1999-03-11 Upjohn Co Substituted tetronic acids useful for treating HIV and other retroviruses
US5840751A (en) * 1993-11-19 1998-11-24 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
EP0729466A1 (en) * 1993-11-19 1996-09-04 PARKE, DAVIS & COMPANY Pyrone derivatives as protease inhibitors and antiviral agents
JP3684426B2 (ja) * 1993-11-19 2005-08-17 パーク・デイビス・アンド・カンパニー プロテアーゼ阻害剤および抗ウイルス剤としての５，６−ジヒドロピロン誘導体
JP3698435B2 (ja) * 1993-11-19 2005-09-21 パーク・デイビス・アンド・カンパニー プロテアーゼ阻害剤および抗ウイルス剤としての５，６−ジヒドロピロン誘導体
US6005103A (en) * 1993-11-19 1999-12-21 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
DE69432056T2 (de) * 1993-11-19 2003-10-09 Parke, Davis & Company Pyron derivate als protease inhibitoren und antivirusmitteln
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
AU5417696A (en) * 1995-03-20 1996-10-08 Upjohn Company, The Substituted tetronic acids useful for treating hiv and other retroviruses
WO1998000173A2 (en) * 1996-07-03 1998-01-08 Pharmacia & Upjohn Company Targeted drug delivery using sulfonamide derivatives
EP1015441B1 (en) * 1997-09-11 2004-05-12 PHARMACIA & UPJOHN COMPANY Process to produce 4-hydroxy-2-oxo-pyrane derivatives useful as protease inhibitors
DE69917237T2 (de) 1998-03-12 2005-05-04 Teijin Ltd. Benzofurylpyron-derivate
EP1281399A3 (en) * 2001-08-01 2004-02-11 Warner-Lambert Company Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
CN102030645A (zh) 2003-10-24 2011-04-27 隆萨股份公司 6,6,6-三卤-3,5-二氧代己酸酯的制备方法
EP2032551B9 (en) * 2006-06-16 2012-02-29 Pharma Mar, S.A. Antitumoral dihydropyran-2-one compounds
UA119963C2 (uk) 2007-12-20 2019-09-10 Фарма Мар, С.А. Протипухлинні сполуки
DE102008055914A1 (de) 2008-11-05 2010-05-06 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acroleinen und ihre Verwendung
CN102177164B (zh) 2008-11-05 2015-02-11 科莱恩金融(Bvi)有限公司 利用烯丙醇/丙烯醛制备二烷基次膦酸、二烷基次膦酸酯和二烷基次膦酸盐的方法,以及它们的用途
DE102008055916A1 (de) 2008-11-05 2010-05-06 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Allylalkoholen und ihre Verwendung
DE102008056341A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von monoaminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
DE102008056342A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
EP2352740B1 (de) 2008-11-07 2014-09-24 Clariant Finance (BVI) Limited Verfahren zur herstellung von dialkylphosphinsäuren, -estern und -salzen mittels acrylsäurederivaten und ihre verwendung
DE102008056339A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von mono-aminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
US8772519B2 (en) 2008-11-11 2014-07-08 Clariant Finance (Bvi) Limited Process for preparing mono-allyl-functionalized dialkylphosphinic acids, salts and esters thereof with allylic compounds, and the use thereof
DE102008060036A1 (de) 2008-12-02 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
DE102008060035A1 (de) 2008-12-02 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
DE102008060535A1 (de) * 2008-12-04 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylether und ihre Verwendung
ES2446666T3 (es) 2008-12-18 2014-03-10 Clariant Finance (Bvi) Limited Procedimiento para la preparación de ácidos etilen-dialquil-fosfínicos, o de sus ésteres y sales, mediante acetileno, y su utilización
DE102008063642A1 (de) 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monocarboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Alkylenoxiden und ihre Verwendung
DE102008063668A1 (de) 2008-12-18 2010-07-01 Clariant International Limited Verfahren zur Herstellung von Alkylphosponsäuren, -estern und -salzen mittels Oxidation von Alkylphosphonigsäuren und ihre Verwendung
DE102008063627A1 (de) 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monohydroxyfunktionalisierten Dialkylphosphinsäuren,-estern und -salzen mittels Ethylenoxid und ihre Verwendung
DE102008064003A1 (de) 2008-12-19 2010-06-24 Clariant International Limited Verfahren zur Herstellung von mono-funktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
DE102008064012A1 (de) 2008-12-19 2010-06-24 Clariant International Limited Halogenfreie Addukte von Alkylphosphonigsäurederivaten und diesterbildenden Olefinen, halogenfreie Verfahren zu deren Herstellung und ihre Verwendung
US20120202814A1 (en) * 2009-10-02 2012-08-09 Università Degli Studi Di Siena Compounds with ddx3 inhibitory activity and uses thereof
CN102690275A (zh) * 2011-03-25 2012-09-26 中国人民解放军第二军医大学 四氢呋喃并[3,4-c]吡喃酮类化合物及其制备方法和用途
CN103044375B (zh) * 2012-12-02 2015-08-12 大理学院 一种二氢吡喃酮化合物及其制备方法和药物用途
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
CN114835694B (zh) * 2022-05-25 2024-06-21 中国科学技术大学 一种在水介质中合成手性3，4-二氢-2h-吡喃类化合物的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1276654A (fr) * 1958-10-01 1961-11-24 Nouveaux dérivés de l'hydroxy-4-alpha-2-pyrone
FR1276645A (fr) * 1959-12-28 1961-11-17 Wild Heerbrugg Ag Objectif de microscope
AU4074789A (en) * 1988-03-01 1989-09-22 Upjohn Company, The Coumarins to inhibit reverse transcriptase in humans

Also Published As

Publication number Publication date
IL107556A0 (en) 1994-02-27
NZ258013A (en) 1997-02-24
EP1203770A1 (en) 2002-05-08
MY119031A (en) 2005-03-31
IL107556A (en) 2001-08-08
KR100314975B1 (ko) 2002-02-28
DE69332292D1 (de) 2002-10-17
ES2182837T3 (es) 2003-03-16
FI120399B (fi) 2009-10-15
AU687368B2 (en) 1998-02-26
NO951899L (no) 1995-07-12
LV13088B (en) 2004-01-20
CA2145661A1 (en) 1994-05-26
SK61695A3 (en) 1995-10-11
CN1090279A (zh) 1994-08-03
CZ107895A3 (en) 1995-12-13
EP0668860A1 (en) 1995-08-30
FI952302A0 (fi) 1995-05-11
EP0668860B1 (en) 2002-09-11
AU5549394A (en) 1994-06-08
PT668860E (pt) 2003-01-31
EP1203770B1 (en) 2005-03-09
ATE290531T1 (de) 2005-03-15
JPH08503216A (ja) 1996-04-09
SK285001B6 (sk) 2006-04-06
BR9307451A (pt) 1999-08-31
PL178653B1 (pl) 2000-05-31
ATE223910T1 (de) 2002-09-15
RU95112465A (ru) 1997-03-20
PL308998A1 (en) 1995-09-18
RU2134691C1 (ru) 1999-08-20
DE69332292T2 (de) 2003-05-28
ES2237624T3 (es) 2005-08-01
WO1994011361A1 (en) 1994-05-26
CN1040321C (zh) 1998-10-21
DE69333771D1 (de) 2005-04-14
HU228126B1 (en) 2012-12-28
HUT71558A (en) 1995-12-28
DK1203770T3 (da) 2005-05-23
NO319914B1 (no) 2005-10-03
NO951899D0 (no) 1995-05-12
PT1203770E (pt) 2005-05-31
ZA938019B (en) 1995-04-28
GEP20094660B (en) 2009-03-25
DE69333771T2 (de) 2006-04-06
CA2145661C (en) 2008-04-01
JP3583127B2 (ja) 2004-10-27
CZ291853B6 (cs) 2003-06-18
HU9501411D0 (en) 1995-06-28
DK0668860T3 (da) 2003-01-20
KR950704290A (ko) 1995-11-17

Similar Documents

Publication Publication Date Title
FI952302A (fi) Pyran-2-onit ja 5,6-dihydropyranonit, jotka ovat käyttökelpoisia HIV:n ja muiden retrovirusten hoidossa
GB2344532A (en) Electromagnetic radiation therapy
TR199801195T2 (xx) Tedavide yararl� kinolin ve kinozilin bile�ikleri.
HUT60138A (en) Process for producing combination compositions suitable for preventing and/or treating benign prostatic hyperplasia
LV12316A (lv) 16-aizvietoti 4-azoandrostani ka 5-alfa-reduktazes izozima 1 inhibitori
CA2163904A1 (en) Use of Indolocarbazole Derivatives to Treat a Pathological Condition of the Prostate
AU3011299A (en) Combination therapy for the treatment of benign prostatic hyperplasia
NO932547L (no) Isoksazolederivater for behandling av irritabelt tarmsyndrom
AU5107085A (en) 1,4-dihydropyridine carboxamide derivatives
EP0748221A4 (en) 7-SUBSTITUTED-4-AZA-STEROID DERIVATIVES AS 5-ALPHA REDUCTASE INHIBITORS
ATE198274T1 (de) 17 beta-aryl-4-aza-steroidderivate
HU9501286D0 (en) Methods and compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
BR9203266A (pt) Composto,formulacao farmaceutica,processo para inibir 5alfa-reductase,processos para tratar hiperplasia benigna da prostata,seborreia e alopecia androgenica
AU5457694A (en) Methods and compositions of (-) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
NO975838L (no) Melatoninagonister for behandling av godartet prostatisk hyperplasi
MX9710075A (es) Antagonistas melatonina para el tratamiento en la hiperplasia prostatica benigna.
AU6374798A (en) Methods and compositions of (+) doxazosin for the treatment of hypertension and benign prostatic hyperplasia
BR8906008A (pt) Aparelho para dilatacao da uretra prostatica e processo para tratamento de hiperplasia prostatica benigna

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: PHARMACIA & UPJOHN COMPANY

PC Transfer of assignment of patent

Owner name: PHARMACIA & UPJOHN COMPANY LLC

Free format text: PHARMACIA & UPJOHN COMPANY LLC

FG Patent granted

Ref document number: 120399

Country of ref document: FI

MA Patent expired